Efficacy and Safety of Pirfenidone in CTD-ILD

Summary

A single-center randomized controlled study will be used to observe the efficacy and safety of pirfenidone on CTD-ILD patients for 24 months. The main research endpoints is the lung function (FVC) at 6 months. The clinical dyspnea score, 6-minute walking distance, index of lung function and imaging indicators are evaluated, as well as primary disease activity and adverse reactions of therapy with glucocorticoid and immunosuppressants up to 24 months.

Timeline

Start

2022-06-22

Primary completion

2025-06-30

Completion

2025-12-01

Drugs

Indications